What is the problem? One of the main problems with drugs disappearing from the Bulgarian market is state regulation, which is expressed in the form of price controls. The Bulgarian government experimented with freezing drug prices in 2013 and 2014, which negatively affected the market and caused …
More »The problem is not parallel export of medicines, but low incomes
Author: Kaloyan Staykov In mid-August, the government published for public discussion warmed-up proposals for reform of the drug policy, with the focus on improving access to medicinal products in the country. The problem with access arises mainly for two reasons: parallel export[1] – it is envisaged to create a restrictive list of medicines whose export can be …
More »New bill in the US liberalizes access to medicines
On August 3, the U.S. Senate unanimously passed a bill that would provide access to unapproved experimental drugs for people with life-threatening illnesses. It’s a major victory for libertarians who argue that state regulations infringe on patients’ rights. The bill, S. 204(115), passed quickly and smoothly in …
More »What does the government's health program for 2017-2021 promise?
This text is an analysis of the government's health care program for the period 2017-2021, published on 02.08.2017 on the website of the Council of Ministers here. Prevention and Prevention: The over-financing of hospital care in the country has created the prerequisites for heavy lobbying in the formation of the budget of the National Health Insurance Fund (NHIF). The costs …
More »Is our drug policy economically effective?
What is the problem with medicines? The problems in Bulgarian healthcare are not only with medicines. The problem of the entire system is actually the inefficient spending of funds, which is getting worse every year. The second problem is that since the establishment of the National Health Insurance Fund (NHIF) until today, its budget has been growing by an average of about 7% per …
More »What happens to the NHIF's expenses for the treatment of oncological diseases? (DATA BY HOSPITALS!)
One of the hot topics that is being discussed on the agenda of the Ministry of Health, the National Health Insurance Fund and the Parliament is chemotherapy drugs and clinical pathways for oncological diseases. Why is the topic important? One of the largest budget items of the National Health Insurance Fund concerns the treatment of oncological diseases. The budget part is heavy, due to the fact that …
More »What does the European Commission recommend to us in healthcare?
In the last few days, there has been talk about the recommendations of the European Commission (EC) regarding the 2017 European Semester and the report on the progress of structural reforms in Bulgaria. In the section "Healthcare", the report emphasizes the following main problems of healthcare in the country: limited access, insufficient funding and poor efficiency. It is important to …
More »What do the parties promise in healthcare?
Healthcare is a cornerstone in the election promises of political parties in Bulgaria. It is one of the most speculated topics when it comes to reforms, development and improvement of the current situation. It is no coincidence that the post of Minister of Health can be compared to an electric chair. …
More »Cheaper drugs? Why not?!
As we have already understood, the budget of the National Health Insurance Fund (NHIF) grows annually and unjustifiably. On the other hand, mortality is increasing, while diseases are showing a constant trend. Theft through referrals has been a known fact for years and is easily noticeable in regional statistics. Since we have begun to dismantle the healthcare system, we must …
More »Theft with medical referrals 101
The article talks about a real Bulgarian municipality and the incident is based on real and public data. We will call it “municipality X”, due to the fact that neither the name of the municipality nor the medical team working on its territory should be discredited. The article will present the state of …
More »
EKIP– Expert Club for Economics and Politics A Different Opinion